Innovative Partnership Reduces Cost Of Bayer's Long-Acting Reversible Contraceptive Implant By More Than 50 Percent

    Innovative Partnership Reduces Cost Of Bayer's Long-Acting Reversible
                Contraceptive Implant By More Than 50 Percent

PR Newswire

LOCATION, Feb. 27, 2013

Initiative will expand access to contraceptives for 27 million women in
low-income countries

LOCATION, Feb. 27, 2013 /PRNewswire-USNewswire/ -- An unprecedented group of
public and private sector partners has finalized an agreement that will make
Jadelle®, an effective, long-acting, reversible contraceptive implant,
available to more than 27 million women in the world's poorest countries at a
more than 50 percent price reduction over the next six years.

The Jadelle Access Program – developed and supported through a partnership
between Bayer HealthCare AG, the Bill & Melinda Gates Foundation, the Clinton
Health Access Initiative (CHAI), the Governments of Norway, the United
Kingdom, the United States and Sweden, and the Children's Investment Fund
Foundation (CIFF) and the United Nations Population Fund (UNFPA) – builds on
momentum generated at the July 2012 London Summit on Family Planning, where
global leaders pledged to provide an additional 120 million women in
developing countries with contraceptive access by 2020. It also supports the
recommendations of the UN Commission on Life-Saving Commodities by helping to
shape global markets in order to increase the availability of quality,
life-saving commodities at an optimal price and volume.

Under the signed agreement, Bayer is reducing the current price of its
contraceptive implant, Jadelle®, from US$18 to US$8.50 per unit, effective 1
January 2013, in more than 50 countries globally, including those deemed least
likely by the United Nations (UN) Secretary-General to meet the Millennium
Development Goals (MDGs) on maternal and child health by 2015. The device,
which has been pre-qualified by the World Health Organization (WHO) since
September 2009, provides effective contraception for women for up to five
years.

"Innovation is the key to our commercial success and at the same time the
basis of our social commitment," said Dr. Jorg Reinhardt, Chief Executive
Officer of Bayer HealthCare AG. "We are delighted to make our life-enhancing
products accessible to as many people as possible, regardless of their income
or where they live, thus making a substantial contribution to improving the
health of women and children in developing countries."

When fully implemented, the Jadelle Access Program will avert more than 28
million unintended pregnancies between 2013 and 2018, and, ultimately, prevent
approximately 280,000 infant and 30,000 maternal deaths. In total, the program
will save an estimated US$250 million in global health costs.

Today, more than 200 million women and girls in developing countries who do
not want to get pregnant lack access to modern contraceptives. Studies have
shown that of the 600 million women in developing countries who are using
modern methods of family planning only 1 to 2 percent use implants, but that a
significantly greater proportion would choose implants if they were
consistently available and supported by counseling and clinical services. In
many programs where implants are offered today, they are one of the fastest
growing methods of choice.

Responding to the urgent call for more effective public-private collaboration
at the London Summit on Family Planning, the partners negotiated this price
reduction to make this underutilized method more affordable and accessible to
women globally, ultimately helping to expand contraceptive options.

"In July 2012, global leaders pledged to provide women around the world with
greater access to more contraceptive options, and today, we are one step
closer to delivering on this promise," said Melinda Gates, co-chair of the
Bill & Melinda Gates Foundation. "We hope this will be the first of many
innovative partnerships that will help give women and girls the power to
create better lives for themselves and their families."

The price of US$8.50 per unit will be available to all entities procuring
Jadelle® from Bayer for use in eligible countries. Large agencies, such as
UNFPA and the U.S. Agency for International Development (USAID), and non-state
providers are currently communicating the price reduction to their country
offices and government partners to ensure that the new price is reflected in
countries' contraceptive procurement plans. Procurement processes and
logistics cycles for Jadelle will remain unchanged.

Existing in-country voluntary family planning programs run by government
agencies and civil society organizations, supported by USAID, UNFPA, the
Norwegian Agency for Development Cooperation (NORAD) and the UK Department for
International Development (DFID), will help facilitate increased access to
this long-acting, reversible contraceptive to provide women and couples with
more family planning options.

Bayer HealthCare AG is also working with other partner groups to develop a
plan for improving service delivery infrastructure and training health
providers to ensure that women have safe, quality access to proper insertion
and removal services, as well as counseling.

Additionally, an initiative is underway that would help family planning civil
society organizations scale up innovative distribution methods, such as social
franchising and mobile clinics. This work is expected to double these
organizations' current capacity for offering implants to broaden method choice
within their programs in 2013, with continued expansion in future years.



SOURCE Bill & Melinda Gates Foundation

Website: http://www.gatesfoundation.org
Contact: : Ulrike Schroeder, Bayer HealthCare AG, +49 30 46 81 922 06,
ulrike.schroeder@bayer.com; Bill & Melinda Gates Foundation, +1-206-709 3400,
media@gatesfoundation.org; Norwegian Ministry of Foreign Affairs: +47 913 95
000; Olivia Campbell, DFID, +44 (0) 20 7023 0600, o-campbell@dfid.gov.uk;
USAID Press Office, +1-202-712 4320, Anette Widholm Bolme, SIDA, +46 8 698 55
55, press@sida.se; Miles Kemplay, CIFF, +44 (0) 20 7121 9254,
mkemplay@ciff.org; or Mandy Kibel, UNFPA, +1 (212) 297 5293, kibel@unfpa.org
 
Press spacebar to pause and continue. Press esc to stop.